Immunodiagnostic Systems Hldgs PLC Launch of IDS-iSYS ACTH assay (9108V)

TIDMIDH

RNS Number : 9108V

Immunodiagnostic Systems Hldgs PLC

02 February 2017

Immunodiagnostic Systems Holdings plc.

2 February 2016

Launch of IDS-iSYS ACTH assay - new assay in the IDS hypertension portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, today launched the IDS-iSYS ACTH assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The IDS-iSYS ACTH assay will become a key assay within the existing IDS portfolio for endocrine hypertension testing.

The IDS-iSYS ACTH assay measures a patient's levels of adrenocorticotropic hormone to allow the assessment of pituitary and adrenal gland function. Together with other clinical and laboratory data it allows the differential diagnosis of hyper- and hypo-cortisolism disorders such as Cushing's syndrome and Addison's disease, as well as the evaluation of other causes of endocrine hypertension.

The Global market size of ACTH testing is estimated to be approximately GBP10-15 million.

For further information:

   Immunodiagnostic Systems Holdings plc                   Tel: [phone] 

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: [phone]

James Steel

Oliver Jackson

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEASAAEFAXEFF

(END) Dow Jones Newswires

February 02, 2017 10:14 ET (15:14 GMT)